NCT06850597View on ClinicalTrials.gov

Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
MCIMCI-AD, Early Stage Alzheimer's DiseaseAlzheimer's Disease
Interventions
DRUG

dimethyl fumarate

480 mg per day

Trial Locations (1)

92-213

RECRUITING

Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz, Lodz

All Listed Sponsors
lead

Medical University of Lodz

OTHER